🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Oswaldo Cruz Foundation clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Brazil register with Oswaldo Cruz Foundation as lead sponsor. Synced 28 Sep 2026
7Current trials
6Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Oswaldo Cruz Foundation is the lead sponsor of 7 current clinical trials in our Brazil register. 6 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Doxycycline and Lenacapavir long-acting. The most-studied condition is HIV Infections.

ClinicalTrials.gov trials by status

  • Recruiting686%
  • Active, closed114%

Trials by phase

  • Not applicable457%
  • Phase 4229%
  • Phase 3114%
01

Clinical trials sponsored by Oswaldo Cruz Foundation

7 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro
NCT07500415 · ClinicalTrials.gov ↗ · Sexually Transmitted Diseases, Syphilis, Gonorrhea
Not applicable Recruiting 2025-10 Brazil
Online Cohort of Sexual and Gender Minorities: Evaluating Digital Interventions to Improve HIV Pre-Exposure Prophylaxis and Antiretroviral Treatment Uptake and Adherence
NCT07772791 · ClinicalTrials.gov ↗ · HIV Infections
Not applicable Recruiting 2026-05 Brazil
ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention
NCT07497594 · ClinicalTrials.gov ↗ · Contact With or Exposure to Human Immunodeficiency Virus
Not applicable Recruiting 2026-02 Brazil
Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro
NCT07584122 · ClinicalTrials.gov ↗ · HIV Infections
Not applicable Recruiting 2025-09 Brazil
Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals
NCT03132311 · ClinicalTrials.gov ↗ · HIV Infections
Phase 4 Recruiting 2017-05 Brazil
Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)
NCT06306300 · ClinicalTrials.gov ↗ · Hepatitis C
Phase 4 Recruiting 2022-07 Brazil
The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines
NCT05507671 · ClinicalTrials.gov ↗ · COVID-19
Phase 3 Active, closed 2021-05 Brazil

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Oswaldo Cruz Foundation trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Oswaldo Cruz Foundation trials

8 conditions
HIV Infections3Sexually Transmitted Diseases1Syphilis1Gonorrhea1Chlamydia Infections1Contact With or Exposure to Human Immunodeficiency Virus1COVID-191Hepatitis C1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in Brazil76

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in HIV Infections

SponsorTrials
ViiV Healthcare21
Kirby Institute2
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida2
Hôpital Européen Marseille2
CellSight Technologies1
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba1
PENTA Foundation1
José Antonio Mata Marín1

Sponsors with the most current trials registered for this condition.

06

Questions about Oswaldo Cruz Foundation trials

How many clinical trials does Oswaldo Cruz Foundation sponsor?

Oswaldo Cruz Foundation is the lead sponsor of 7 current trials on ClinicalTrials.gov in our Brazil register, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.

Are Oswaldo Cruz Foundation trials recruiting?

Yes. 6 of its 7 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Oswaldo Cruz Foundation testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Doxycycline (1) and Lenacapavir long-acting (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 28 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.